Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D
Neurology. 1981 Jun;31(6):675-82. doi: 10.1212/wnl.31.6.675.
Pergolide mesylate, a semisynthetic ergoline and a potent, long-acting central dopamine agonist, was tested in 13 patients with advanced Parkinson disease and diurnal oscillations in performance ("wearing-off" or "on-off" phenomena or both) whose response to levodopa had diminished considerably. Among all nine patients who completed the initial clinical trial, pergolide alone (two patients) or combined with levodopa (seven patients) had a marked antiparkinson effect. There was a significant reduction (p less than 0.05) in rigidity, bradykinesia, gait disorder and total Parkinson disease disability score. Pergolide had a marked effect in all the patients with "wearing-off" or "on-off" phenomena or both, resulting in a significant increase (p less than 0.01) in the duration of the time patients were "on." the number of hours in which patients were "on" increased from 3.8 +/- 0.5 (SEM) to 11.4 +/0 ).8 (SEM). The main daily dose of pergolide was 2.4 mg (range, 2 to 5 mg). Ten months later, all nine patients are doing well. Pergolide is an effective drug in patients with advanced Parkinson disease and reduces "on-off" phenomena.
甲磺酸培高利特是一种半合成麦角灵，是一种强效、长效的中枢多巴胺激动剂，在13例晚期帕金森病且存在日间功能波动（“剂末现象”或“开-关现象”或两者皆有）且对左旋多巴反应明显减弱的患者中进行了试验。在完成初始临床试验的所有9例患者中，单独使用培高利特（2例患者）或与左旋多巴联合使用（7例患者）均有显著的抗帕金森病作用。强直、运动迟缓、步态障碍及帕金森病整体残疾评分均有显著降低（p<0.05）。培高利特对所有有“剂末现象”或“开-关现象”或两者皆有的患者均有显著作用，使患者“开”的时间显著增加（p<0.01）。患者“开”的小时数从3.8±0.5（标准误）增加到11.4±0.8（标准误）。培高利特的每日主要剂量为2.4mg（范围为2至5mg）。10个月后，所有9例患者情况良好。培高利特对晚期帕金森病患者是一种有效的药物，可减少“开-关现象”。
